Xiaoling Ma | Medicine | Best Researcher Award

Posted on by sciencefather

Prof. Xiaoling Ma | Medicine | Best Researcher Award

Chief physician | The first hospital of Lanzhou university | China

Dr. Xiaoling Ma is a distinguished Chief Physician and Associate Professor, currently serving as the Director of the Reproductive Medicine Center at The First Hospital of Lanzhou University. With over two decades of experience in reproductive medicine, she has made significant contributions to the advancement of assisted reproductive technology (ART). Dr. Ma is a nationally recognized expert in ART management and holds key positions in several prestigious reproductive medicine organizations in China. Her expertise encompasses reproductive endocrinology, fertility preservation, and genetic screening technologies.

Profile👤

Scopus

Strengths for the Awards✨

✅ Extensive Research Contributions: Xiaoling Ma has published over 30 articles in SCI and core Chinese journals, indicating a strong research output. Recent publications in Biomedicine & Pharmacotherapy, Reproductive Sciences, and BMC Medical Genomics highlight her contributions to reproductive medicine.

✅ Leading Research and Innovation: She has led multiple national and provincial research projects, including studies on reproductive genetics, fertility preservation, and endometriosis mechanisms.

✅ Academic and Professional Influence: As a chief physician, associate professor, and director of the Reproductive Medicine Center, her influence extends to clinical practice, academic mentorship, and policy advisory roles.

✅ Editorial and Professional Leadership: Serving as the Chinese editor for Human Reproduction Update and holding key roles in reproductive medicine associations in China demonstrate her leadership in the field.

🎓 Education

Dr. Xiaoling Ma obtained her Master’s degree in Medicine from a renowned Chinese institution. She has pursued extensive postgraduate training and specialized programs in reproductive medicine, refining her knowledge in assisted reproductive technology, reproductive endocrinology, and genetic screening. Her continuous pursuit of academic excellence has positioned her as a leading educator and mentor in reproductive healthcare.

💼 Experience

With a distinguished career spanning over 20 years, Dr. Ma has been instrumental in pioneering and implementing ART techniques. She has successfully led numerous national and provincial medical projects in China, focusing on fertility evaluation, genetic screening, and reproductive health. In addition to her clinical practice, she plays a pivotal role in policy-making and regulatory aspects of reproductive medicine, ensuring the ethical implementation of ART procedures. As an educator, she has trained and mentored countless physicians, enhancing the field of reproductive medicine across China.

🔬 Research Interests On Medicine

Dr. Ma’s research is dedicated to three-level prevention and control of birth defects, fertility preservation in cancer patients, and the application of genetic screening in reproductive health. She explores the mechanisms behind endometriosis, recurrent pregnancy loss, and infertility, aiming to develop innovative treatment protocols. Her contributions to preimplantation genetic testing (PGT) and reproductive immunology have significantly influenced reproductive healthcare in China and beyond.

🏆 Awards and Recognitions

Dr. Ma has been recognized for her outstanding contributions to reproductive medicine and has received multiple accolades at the national and provincial levels. She is an esteemed member of leading reproductive medicine societies and has played a crucial role in shaping policies related to ART in China. She has also been actively involved in national academic conferences, furthering research and clinical advancements in reproductive health.

📚 Publications

Dr. Ma has published over 30 research articles in SCI-indexed and Chinese core journals. Below are some of her notable publications:

  1. Guan, D., Sun, W., Gao, M., Chen, Z., & Ma, X. (2024). Immunologic insights in recurrent spontaneous abortion: Molecular mechanisms and therapeutic interventions. Biomedicine & Pharmacotherapy, 177, p.117082. [Cited by articles]
  2. Liu, L., Liu, Y., Tian, Y., Cao, Y., Wang, T., Mi, S., Yang, R., Liu, S., Ma, X., & Wang, J. (2024). Identification of differentially expressed mRNAs and lncRNAs contributes to elucidation of underlying pathogenesis and therapeutic strategy of recurrent implantation failure. Reproductive Sciences, pp.1-14. [Cited by articles]
  3. Wang, T., Zhang, L., Gao, W., Liu, Y., Yue, F., Ma, X., & Liu, L. (2024). Transcriptome-wide N6-methyladenosine modification profiling of long non-coding RNAs in patients with recurrent implantation failure. BMC Medical Genomics, 17(1), p.251. [Cited by articles]
  4. Guan, D., Zhao, L., Shi, X., Ma, X., & Chen, Z. (2023). Copper in cancer: from pathogenesis to therapy. Biomedicine & Pharmacotherapy, 163, p.114791. [Cited by articles]

🔚 Conclusion

Dr. Xiaoling Ma is a pioneering figure in reproductive medicine, dedicated to advancing ART and genetic screening technologies. Her extensive clinical expertise, innovative research, and leadership in reproductive medicine make her a highly respected figure in her field. Through her work, she continues to impact countless lives, improving fertility treatments and reproductive healthcare policies. Her commitment to teaching, research, and patient care ensures a lasting legacy in reproductive medicine.

Qianghua Lv | Medicine | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Qianghua Lv | Medicine | Best Researcher Award

Shandong Academy of Agricultural Sciences | China

Dr. Qianghua LV is an Associate Researcher at the Institute of Animal Science and Veterinary Medicine (IASVM), Shandong Academy of Agricultural Sciences (SAAS). He earned his Ph.D. in Veterinary Pharmacology under the mentorship of Prof. DENG Xuming at Jilin University in 2020. His research focuses on developing novel therapeutic strategies targeting bacterial virulence factors, including bacterial hemolysin, Type III Secretion System (T3SS), and Type IV Pili (TFP). His work contributes significantly to understanding anti-infective mechanisms and advancing new drug development against bacterial infections.

Profile👤

ORCID

Strengths for the Awards✨

  • High-Impact Research Focus – Dr. LV Qianghua’s work on anti-infection mechanisms and natural compound-based drug development aligns with global health priorities, particularly in combating superbacterial infections. His research on bacterial virulence factors like hemolysin, T3SS, and TFP contributes to the development of novel antimicrobial strategies.

  • Quality Publications in Reputable Journals – He has multiple first-author and co-first-author publications in high-impact journals, such as Journal of Cellular and Molecular Medicine and Applied Microbiology and Biotechnology. These papers focus on novel antibacterial mechanisms and natural product inhibitors, demonstrating both innovation and scientific rigor.

  • Translational Impact – His research not only advances basic microbiology but also holds significant translational potential in developing new antibacterial therapies, an area of urgent medical need due to rising antibiotic resistance.

  • Collaborative and Multi-Disciplinary Approach – His collaborations with researchers across multiple disciplines (pharmacology, microbiology, and veterinary medicine) enhance the applicability of his findings beyond veterinary science, benefiting both animal and human health.

  • Contribution to Veterinary Medicine – As an Associate Researcher at the IASVM, SAAS, Dr. LV contributes significantly to veterinary pharmacology, a field essential for both agricultural and public health. His work has implications for livestock disease management and food safety, making it highly relevant for both academia and industry.

🎓 Education

  • Ph.D. in Veterinary Pharmacology, Jilin University, 2020
    • Advisor: Prof. DENG Xuming
    • Research Focus: Anti-infection mechanisms of natural compounds targeting bacterial virulence factors

💼 Experience

  • Associate Researcher, IASVM, SAAS (2020–Present)
    • Conducting research on antibacterial strategies targeting virulence factors
    • Screening natural compounds for inhibitory effects on bacterial infections
    • Developing new therapeutic agents against superbacterial infections

🔬 Research Interests On Medicine

  • 🦠 Discovery and screening of novel targets and lead compounds against superb acterial infections
  • 💊 Synergistic antibacterial effects and mechanisms of natural compounds and antimicrobial agents

📚 Selected Publications

  • Title: Inhibition of the type III secretion system by syringaldehyde protects mice from Salmonella enterica serovar Typhimurium
    Authors: Lv Q(#), Chu X(#), Yao X, Ma K, Zhang Y*, Deng X*
    Publication Year: 2019
    Journal: Journal of Cellular and Molecular Medicine

  • Title: Identification of the natural product paeonol derived from peony bark as an inhibitor of the Salmonella enterica serovar Typhimurium type III secretion system
    Authors: Lv Q(#), Li S(#), Wei H, Wen Z, Wang Y, Tang T, Wang J, Xia L*, Deng X*
    Publication Year: 2020
    Journal: Applied Microbiology and Biotechnology

  • Title: Phloretin potentiates polymyxin E activity against Gram-negative bacteria
    Authors: Du R(#), Lv Q(#), Hu W, Hou X, Zhou Y, Deng X, Sun L, Li L, Deng Y, Wang J
    Publication Year: 2021
    Journal: Life Sciences

  • Title: Commercialized artemisinin derivatives combined with colistin protect against critical Gram-negative bacterial infection
    Authors: Zhou Y, Liu B, Chu X, Su J, Xu L, Li L, Deng X, Li D*, Lv Q*, Wang J*
    Publication Year: 2022
    Journal: Communications Biology

  • Title: Isoflavone glucoside genistin, an inhibitor targeting Sortase A and Listeriolysin O, attenuates the virulence of Listeria monocytogenes in vivo and in vitro
    Authors: Liu M(#), Lv Q(#), Xu J, Liu B, Zhou Y, Zhang S, Shen X, Wang L
    Publication Year: 2023
    Journal: Biochemical Pharmacology

🔚 Conclusion

Dr. LV Qianghua has dedicated his research to developing innovative antibacterial strategies, focusing on targeting bacterial virulence factors. His contributions in natural compound screening and new drug development have advanced the fight against superbacterial infections. With numerous impactful publications and ongoing research, he continues to make significant strides in veterinary medicine and pharmacology.

Yang Xu | Medicine | Best Researcher Award

Posted on by sciencefather

Dr. Yang Xu | Medicine | Best Researcher Award

Associate chief physician | Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital | China

Yang Xu is an Associate Chief Physician, Associate Professor, and Graduate Supervisor at the Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital. Specializing in the early diagnosis and personalized treatment of lung tumors, Dr. Xu has made significant contributions to respiratory medicine and oncology. As a leading expert in the field, he has played a pivotal role in advancing immune purification and cell therapy, earning widespread recognition for his scientific achievements.

Profile

ORCID

Strengths for the Awards

✅ Expertise in Lung Tumor Diagnosis & Treatment: Yang Xu specializes in the early diagnosis and personalized treatment of lung tumors, which is a crucial area in respiratory and critical care medicine.

✅ Strong Research Contributions: With 6 funded research projects, including National Natural Science Foundation of China and key national R&D plans, his research impact is significant.

✅ Recognition & Patents: Winning 1 medical science and technology progress award and holding 4 national invention patents showcase his innovation and contribution to medical advancements.

✅ Publication Record: Publishing 40 research papers, including 20 SCI-indexed papers, and editing 5 monographs as a deputy principal author indicates a high level of scholarly contribution.

✅ Leadership & Influence: Holding leadership positions in prestigious medical associations such as the Chinese Medical Association and Beijing Medical Association reflects his influence in the field.

🎓 Education

Dr. Xu received his medical education and advanced training in respiratory and critical care medicine, equipping him with the expertise to diagnose and treat complex lung diseases. His academic journey has been marked by rigorous research and continuous professional development in cutting-edge medical technologies.

👨‍⚕️ Experience

With extensive experience in respiratory and critical care medicine, Dr. Xu has led multiple national research projects, including those funded by the National Natural Science Foundation of China and the national key R&D plan. As an esteemed educator and mentor, he has guided numerous students in the field, shaping the next generation of medical professionals. His leadership extends to prestigious roles such as Deputy Leader of the Immune Purification and Cell Therapy Group under the Chinese Medical Association and Deputy Chairman of the Lung Cancer Group in the Respiratory Branch of the Beijing Medical Association.

🔬 Research Interests On Medicine

Dr. Xu’s research focuses on:

  • Lung Tumor Diagnosis & Treatment – Advancing early detection and precision therapy.
  • Immune Checkpoint Inhibitor Pneumonia – Contributing to China’s first expert consensus.
  • Strategic Advanced Electronic Materials – Investigating innovative medical applications.
  • Immune Purification & Cell Therapy – Exploring novel therapeutic strategies in respiratory medicine.

🏆 Awards

Dr. Xu has received numerous accolades for his contributions to medical science, including:

  • Medical Science & Technology Progress Award 🏅
  • 4 National Invention Patents 🏅🏅🏅🏅
  • Excellent Doctor & Excellent Teacher Titles 🏆 (Multiple times)
  • Selected as China’s High-Level Scientific and Technological Innovation Talent 🌟

📚 Publications

  1. Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel flcn Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation
    • Authors: Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang
    • Year: 2025
  2. [Clinical diagnosis and treatment of lung cancer combined with interstitial lung disease]
    • Author: Xu Y
    • Year: 2024
  3. Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer
    • Authors: Yabin Chen, Fang Z, Tang Y, Jin Y, Guo C, Hu L, Xu Y, Ma X, Gao J, Xie M et al.
    • Year: 2021
  4. Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary-care hospital: A 6-year retrospective study
    • Authors: Xu Y, Wang Z, Li W, Zhu Q, Liang Z
    • Year: 2021
  5. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
    • Authors: Huang A, Xu Y, Zang X, Wu C, Gao J, Sun X, Xie M, Ma X, Deng H, Song J et al.
    • Year: 2021
  6. Perfluorocarbon Protects against Lipopolysaccharide-Induced Apoptosis of Endothelial Cells in Pulmonary Microvessels
    • Authors: Xu Y, Wu T, Wang P, Liang ZX, Shi SS, Xu SF, Liu XJ, Tian Q
    • Year: 2021
  7. Lung cancer treatment in the era of immunotherapy
    • Authors: Xu Y, Liang-an Chen
    • Year: 2020
  8. The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial
    • Authors: Minghui Zhu, Yang Z, Hang Yu, Zhu Q, Xu Y, Li Y, Li C, Zhao W, Zhixin Liang, Liang-an Chen
    • Year: 2020
  9. Identification of differentially expressed genes in hip cartilage with femoral head necrosis, based on genome‑wide expression profiles
    • Authors: Li WC, Bai L, Xu Y, Xu RJ, Hou WB
    • Year: 2019
  10. Cystic and solitary nodular pulmonary metastases in a patient with low-grade endometrial stromal sarcoma: A case report and literature review
  • Authors: Xu Y, Zhixin Liang, Guo JT, Su X, Lu YL, Guan XZ
  • Year: 2019

🔚 Conclusion

Yang Xu is a distinguished leader in respiratory and critical care medicine, driving innovation in lung cancer treatment and immune-related diseases. His contributions to research, education, and clinical practice continue to shape the future of respiratory medicine, making a lasting impact on both national and global healthcare communities.

Qun Zhao | Medicine | Outstanding Scientist Award

Posted on by sciencefather

Prof. Qun Zhao | Medicine | Outstanding Scientist Award

The Fourth Hospital of Hebei Medical University | China

Qun Zhao is a distinguished medical professional affiliated with the Third Department of Surgery at the Fourth Hospital of Hebei Medical University. With extensive experience in surgical oncology, he has contributed significantly to the advancement of gastric and gastrointestinal cancer treatments. As a committed researcher and clinician, Dr. Zhao is an active member of multiple professional committees, driving innovation and excellence in cancer therapy.

Profile👤

ORCID

Strengths for the Awards

✅ Extensive Leadership in Oncology Research: Qun Zhao holds key positions in multiple national committees related to gastric cancer, gastrointestinal mesenchymal tumors, peritoneal tumors, tumor support therapy, and surgical nutrition. These roles highlight significant contributions to cancer research and treatment.

✅ Institutional and Professional Affiliations: Being part of the Fourth Hospital of Hebei Medical University, a reputed institution, strengthens credibility. His involvement in China’s Anti-Cancer Association further establishes his expertise in the field.

✅ Contributions to Cancer Surgery & Nutrition: Given the focus on gastric and peritoneal tumors, surgical oncology, and nutrition, Qun Zhao’s work aligns with impactful research that directly benefits patients and advances medical science.

✅ Editorial and Research Contributions: While specific journal publications, patents, or citation indices are not provided, editorial appointments and professional memberships suggest recognition by the academic community.

✅ Potential for Industry Impact: If consultancy or industry projects exist (to be detailed), they could indicate translational research, bridging academia with practical medical applications.

Education 🎓

Dr. Qun Zhao completed his medical education and specialized training in surgical oncology at renowned institutions. His academic journey has been marked by a commitment to continuous learning and specialization in gastrointestinal malignancies and surgical techniques.

Experience 🌟

Dr. Zhao holds a prominent position in the medical field, serving in various leadership roles, including the Standing Committee memberships in multiple prestigious oncology and surgical nutrition groups. His expertise extends across peritoneal tumor management, gastric cancer treatment, and gastrointestinal mesenchymal tumors. His clinical acumen and research contributions have had a significant impact on cancer treatment methodologies.

Research Interests On Medicine 🔬

Dr. Zhao’s research focuses on innovative surgical techniques, tumor nutrition, and multimodal cancer treatment strategies. His work aims to improve patient outcomes through targeted therapies and advanced surgical interventions. His ongoing projects include groundbreaking research in peritoneal metastases and gastrointestinal stromal tumors.

Awards 🏆

Dr. Zhao has been recognized for his outstanding contributions to surgical oncology and cancer research. His accolades include awards from national and international oncology societies for his pioneering work in gastric and peritoneal tumors.

Publications 📚

Dr. Zhao has authored numerous peer-reviewed articles in high-impact journals. Some of his key publications include:

  • Pioneering case: Robot-assisted remote radical distal gastrectomy for gastric cancer based on 5G communication technology
    • Authors: Honghai Guo, Yuan Tian, Jia Shi, Peigang Yang, Jiaxuan Yang, Pingan Ding, Xuefeng Zhao, Zhidong Zhang, Qun Zhao
    • Publication Year: 2024
    • DOI: 10.1016/j.isurg.2024.01.004
  • Comment on ‘Hand grip strength‐based cachexia index as a predictor of cancer cachexia and prognosis in patients with cancer’ by Xie et al.
    • Authors: Ping’an Ding, Jiaxiang Wu, Haotian Wu, Chenyu Sun, Muzi Meng, Scott Lowe, Yuan Tian, Honghai Guo, Lingjiao Meng, Qun Zhao
    • Publication Year: 2023
    • DOI: 10.1002/jcsm.13298
  • Comment on: ‘Triceps skinfold‐albumin index significantly predicts the prognosis of cancer cachexia: A multicentre cohort study’ by Yin et al.
    • Authors: Ping’an Ding, Haotian Wu, Jiaxiang Wu, Chenyu Sun, Muzi Meng, Peigang Yang, Yang Liu, Lingjiao Meng, Qun Zhao
    • Publication Year: 2023
    • DOI: 10.1002/jcsm.13304
  • Safety and efficacy of carbon nanoparticle suspension injection and indocyanine green tracer-guided lymph node dissection during robotic distal gastrectomy in patients with gastric cancer
    • Authors: Yuan Tian, Yecheng Lin, Honghai Guo, Yiyang Hu, Yong Li, Liqiao Fan, Xuefeng Zhao, Dong Wang, Bibo Tan, Qun Zhao
    • Publication Year: 2022
    • DOI: 10.1007/s00464-021-08630-8
  • Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
    • Authors: Yuan Tian, Qun Zhao, Yong Li, Liqiao Fan, Zhidong Zhang, Xuefeng Zhao, Bibo Tan, Dong Wang, Peigang Yang, Nicola Silvestris
    • Publication Year: 2021
    • DOI: 10.1155/2021/5590626

Conclusion 🥇

Dr. Qun Zhao’s dedication to oncology research and patient care continues to influence the medical community. His innovative approaches in surgery and therapeutic nutrition play a pivotal role in advancing cancer treatment. His contributions, both in research and clinical practice, underscore his commitment to improving healthcare outcomes globally.